

**DRUG NAME: Mitoxantrone**

**SYNONYM(S):** Dihydroxyanthracenedione, <sup>1</sup> DHAD <sup>1,2</sup>

**COMMON TRADE NAME(S):** NOVANTRONE® (USA)

**CLASSIFICATION:** intercalating agent-antitumour antibiotic

*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.*

**MECHANISM OF ACTION:**

Mitoxantrone is a synthetic anthracenedione that is structurally similar to doxorubicin and daunorubicin. <sup>2,3</sup> It was synthesized with the goal to reduce anthracycline side effects, particularly cardiotoxicity. <sup>4</sup> Mitoxantrone inhibits DNA repair by inhibiting topoisomerase II <sup>3,5</sup> which results in fragmentation of DNA. <sup>6</sup> Mitoxantrone is an immunosuppressive agent <sup>3,5</sup> that may also generate free radicals, inhibit protein kinase C, cause electrostatic DNA cross-links, and induce apoptosis. <sup>2</sup> Although maximally cytotoxic in the S-phase, mitoxantrone is not cell cycle phase-specific. <sup>2,7</sup> Cross-resistance with anthracyclines has been demonstrated. <sup>2</sup>

**PHARMACOKINETICS:**

Oral Absorption	poor <sup>5</sup>	
Distribution	extensive tissue distribution; 3X greater AUC in patients with severe hepatic dysfunction	
	cross blood brain barrier?	not to an appreciable extent
	volume of distribution <sup>5</sup>	14 L/kg; distributes into pleural fluid, kidney, thyroid, liver, heart, and red blood cells
	plasma protein binding <sup>5</sup>	>95%; 76% to albumin
Metabolism	hepatic, pathways undetermined	
	active metabolite(s)	no information found
	inactive metabolite(s) <sup>8</sup>	yes
Excretion	urine <sup>2,5</sup>	6-11%; 65% unchanged
	feces <sup>5</sup>	25%; 65% unchanged
	terminal half life	23-215 h; prolonged by hepatic impairment
	clearance <sup>9</sup>	10.9-37.4 L/hr/m <sup>2</sup>
Elderly	decreased clearance	

Adapted from standard reference <sup>3</sup> unless specified otherwise.

**USES:**

**Primary uses:**

\*Leukemia, including acute non-lymphocytic  
Prostate cancer <sup>10</sup>

**Other uses:**

\*Breast cancer  
\*Hepatoma  
\*Lymphoma  
Pediatric sarcoma <sup>5</sup>

\*Health Canada approved indication

**SPECIAL PRECAUTIONS:**

**Contraindications:**

- history of hypersensitivity reaction to anthracyclines or mitoxantrone <sup>3</sup>

**Caution:**

- when used in **combination regimens**, the initial dose should be reduced by 2-4 mg/m<sup>2</sup> below the recommended dose for single-agent usage <sup>3</sup>
- **cardiac toxicity** is a risk of mitoxantrone therapy that may be manifested by acute or delayed events; risk factors for developing mitoxantrone-induced cardiotoxicity include <sup>3</sup>
  - high cumulative dose
  - previous therapy with other anthracyclines or anthracenediones
  - prior or concomitant radiotherapy to the mediastinal/pericardial area
  - pre-existing heart disease [left ventricular ejection fraction (LVEF) <50% or a clinically-significant reduction in LVEF]
  - concomitant use of other cardiotoxic drugs.

**Carcinogenicity:** Studies not performed to date. Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) have been reported when used alone but more so when used with other antineoplastic agents and/or radiation. <sup>3</sup>

**Mutagenicity:** Mitoxantrone is mutagenic in microbial mutagenicity tests. Mitoxantrone is clastogenic in mammalian *in vivo* chromosome tests. However, at doses approximating clinical use levels, the clastogenic effect is reversible. The reversibility of the clastogenic effect and the absence of a dominant lethal effect may suggest that there is little mutagenic risk to humans receiving mitoxantrone for clinical use. <sup>11</sup>

**Fertility:** Amenorrhea and a typically reversible reduction in spermatogenesis have been reported in humans. <sup>3,8,12</sup> In reproductive studies in rats, mitoxantrone had no effect on reproductive performance, fertility, or gestation at the highest tolerated doses. <sup>11</sup>

**Pregnancy:** There are no controlled studies in pregnant women. In animal studies, fetal uptake in pregnant rats was negligible and the amniotic fluid contained no appreciable amount of drug, indicating that the placenta was an effective barrier. Mitoxantrone was not teratogenic in rats or rabbits. Decreased fetal body weight and retarded fetal kidney development were reported more frequently in treated rats (at doses 0.05 times the recommended human dose). Premature delivery was reported with a higher incidence in treated rabbits (at doses 0.01 times the recommended human dose). Pregnancy tests are recommended prior to treatment with mitoxantrone. <sup>11</sup>

**Breastfeeding** is not recommended due to secretion into breast milk. Significant concentrations of mitoxantrone have been reported in human milk 28 days after the last administration of the drug. <sup>11</sup>

**SIDE EFFECTS:**

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important. <sup>13</sup>

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b><i>bold, italics</i></b>	
allergy/immunology	allergic reactions; including anaphylaxis (<1%)
	<b><i>anemia</i></b> (5-75%)

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b>bold, italics</b>	
blood/bone marrow/ febrile neutropenia	<b>leukopenia</b> (9-100%); nadir typically occurs on day 10 with recovery by day 21
	<b>myelosuppression</b> ; dose-limiting; severe myelosuppression is rare
	thrombocytopenia (33-39%)
cardiovascular (arrhythmia)	arrhythmia (3-18%); including sinus bradycardia
	ECG changes (11%)
cardiovascular (general) (see paragraph following <b>Side Effects</b> table)	<b>cardiomyopathy</b>
	<b>CHF</b> (2-5%); may occur during and months to years after treatment; deaths have occurred
	decreased left ventricular ejection fraction ( $\leq 13\%$ ); may occur during and months to years after treatment
	hypertension (4%)
	hypotension
	ischemia (5%)
constitutional symptoms	myocardial infarction
	diaphoresis (9%)
	fatigue ( $\leq 39\%$ )
	fever (6-78%)
dermatology/skin	weight changes (13-17%)
	<b>extravasation hazard</b> : irritant <sup>14</sup> ; see paragraph following <b>Side Effects</b> table
	alopecia* (15-61%, severe 1%); typically mild; case reports of selective alopecia of white but not dark hair <sup>8</sup>
	bruising (6-11%)
	nail pigmentation
gastrointestinal	onycholysis (11%)
	<b>emetogenic potential</b> : low to low-moderate <sup>15</sup>
	anorexia (22-25%)
	constipation (10-16%)
	diarrhea* (4-47%) <sup>5,8</sup>
	dyspepsia (5-14%)
	nausea and vomiting* (10-35%, severe 4%) <sup>3,8</sup> typically mild and transient
	stomatitis/mucositis* (4-54%, severe <1%); typically occurs within 1 week of treatment <sup>8</sup>
ulcers (10%)	
hemorrhage	gastrointestinal bleed (2-16%)
	hemorrhage* (6%)
hepatobiliary/pancreas	hepatic toxicity* (<1%) <sup>8</sup> ; severe impairment reported in leukemic patients

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b><i>bold, italics</i></b>	
infection	infection* including urinary tract (7-32%), upper respiratory tract (7-53%), pneumonia (9%)
lymphatics	edema (10-31%)
metabolic/laboratory	hyperglycemia (10-31%); likely related to concurrent steroid administration <sup>13</sup>
	hyperuricemia; see paragraph following <b>Side Effects</b> table
	hypocalcemia (10%)
	hypokalemia (7-10%)
	hyponatremia (9%)
	increased blood urea nitrogen (22%)
	increased liver enzymes ( $\leq 37\%$ ) <sup>5,8</sup>
	increased serum creatinine (13%)
proteinuria (6%)	
musculoskeletal	weakness (24%)
neurology	anxiety (5%)
	confusion
	depression (5%)
	drowsiness
	paraesthesia
	seizures (2-4%)
ocular/visual	blue discolouration of the sclera (<1%); reversible
	blurred vision (3%)
	conjunctivitis (5%)
pain	headache (6-13%)
	pain (8-41%); including abdominal pain (9-15%), back pain (8%), myalgia (5%), arthralgia (5%)
pulmonary	cough (5-13%)
	dyspnea (6-18%)
	rhinitis/sinusitis (5-6%)
renal/genitourinary	blue-green colouration of urine (6-11%); typically occurs for 24h after treatment
	hematuria (11%)
	renal toxicity (8%)
secondary malignancy	AML and MDS (~1-2%)
sexual/reproductive function	amenorrhea (28-53%), menstrual disorder (26-61%)
	impotence (7%)
	reduction in spermatogenesis; typically reversible <sup>3,8,12</sup>

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b>bold, italics</b>	
syndromes	tumour lysis syndrome (<1%)

Adapted from standard reference <sup>3,5</sup> unless specified otherwise.

***\*In patients with leukemia***, due to higher doses used, the side effects profile may differ; the following toxicities have been reported <sup>5,7</sup>:

- diarrhea (9-13%)
- increased incidence of bleeding and infection; sepsis (31-34%)
- moderate nausea or vomiting (8%)
- moderate or severe alopecia (11%)
- moderate or severe stomatitis/mucositis (9-29%)
- moderate or severe jaundice or hepatitis (8%)

***Cardiotoxicity*** is thought to be due to free radical damage as myocardial tissue is susceptible to these highly reactive species. <sup>16</sup> Anthracycline cardiotoxicity may present with early or late effects. <sup>17,18</sup> The following information applies to all anthracyclines, anthracenediones and mitoxantrone. <sup>16,18,19</sup>

***Early cardiotoxic effects*** are not dose-related and may present from mild ECG changes to life-threatening arrhythmias. <sup>16,17,19</sup> These events may occur during or immediately after a single dose of anthracycline treatment, <sup>16,19</sup> but do not predict subsequent development of delayed cardiotoxicity and are not considered indications for suspension of therapy. <sup>16,17,19-22</sup>

***Late cardiotoxic effects***, which are dose-related and clinically the most important type of cardiotoxic effect, present as reduced LVEF or symptomatic CHF, and typically occur weeks to years after completion of treatment. <sup>16,18-21</sup> Abnormalities in LVEF are associated with all the anthracyclines and their derivatives. <sup>18</sup> LVEF changes are related to the total cumulative dose, are irreversible and refractory to medical therapy. <sup>16,23</sup>

***Prevention and treatment:*** Cardiac assessment should occur at baseline and throughout therapy. Monitor for symptomatic congestive heart failure (CHF) or reduced left ventricular ejection fraction (LVEF). Sensitive, non-invasive methods to measure LVEF include radionuclide angiography (RNA), MUGA, or echocardiogram. <sup>18</sup> Late cardiotoxic effects may be prevented by stopping treatment with the associated anthracycline once patients have reached the suggested maximum cumulative dose. <sup>16,23</sup> Management of anthracycline cardiotoxicity includes discontinuation of the drug and initiating standard treatment of CHF. <sup>18</sup>

Cardiotoxicity risk can be reduced but not eliminated with the use of alternative anthracyclines (i.e., epirubicin or liposomal doxorubicin) or by altering the frequency of administration (once a week vs. once every 3 weeks, or continuous infusion). <sup>18</sup> Cardioprotectant therapy with dexrazoxane may be considered for patients with cumulative doxorubicin-equivalent doses greater than 300 mg/m<sup>2</sup>. <sup>19,24,25</sup>

Cumulative doses should be calculated and account for all previous anthracyclines or anthracenediones received during the patient's lifetime. For further information on suggested conversion factors and monitoring thresholds for anthracyclines, see [Dose Conversion for Anthracyclines Exposure](#) in Appendix.

***Hyperuricemia*** may result from cell lysis by mitoxantrone and may lead to electrolyte disturbances or acute renal failure. <sup>35</sup> It is most likely with highly proliferative tumours of massive burden, such as leukemias, high-grade lymphomas, and myeloproliferative diseases. The risk may be increased in patients with preexisting renal dysfunction, especially ureteral obstruction. Suggested prophylactic treatment for high-risk patients <sup>36</sup>:

- aggressive hydration: 3 L/m<sup>2</sup>/24 hr with target urine output >100 ml/h
- if possible, discontinue drugs that cause hyperuricemia (e.g., thiazide diuretics) or acidic urine (e.g., salicylates)
- monitor electrolytes, calcium, phosphate, renal function, LDH, and uric acid q6h x 24-48 hours
- replace electrolytes as required

- allopurinol 600 mg po initially, then 300 mg po q6h x6 doses, then 300 mg po daily x 5-7 days  
Urine should be alkalinized only if the uric acid level is elevated, using sodium bicarbonate IV or PO titrated to maintain urine pH>7. Rasburicase (FASTURTEC®) is a novel uricolytic agent that catalyzes the oxidation of uric acid to a water-soluble metabolite, removing the need for alkalinization of the urine.<sup>37</sup> It may be used for treatment or prophylaxis of hyperuricemia; however, its place in therapy has not yet been established. Aluminum hydroxide (AMPHOGEL®) may be added orally if phosphate becomes elevated. If aluminum hydroxide has been added, discontinue sodium bicarbonate.<sup>38</sup>

**Local tissue damage** may occur at the infusion site and include erythema, swelling, pain, burning, rash, phlebitis, and/or blue discoloration of the skin. The nonvesicant properties of mitoxantrone minimize the possibility of severe reactions following extravasation and serious local reactions are rare. However, extravasation can result in tissue necrosis with a resultant need for debridement and skin grafting.<sup>11</sup> For more details on the prevention and management of anthracycline extravasation, refer to BC Cancer [Systemic Therapy Policy III-20: Prevention and Management of Extravasation of Chemotherapy](#).

### INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
quinolones (e.g., ciprofloxacin) <sup>39</sup>	delayed, moderate, possible; the antimicrobial effect of quinolones may be decreased	quinolone absorption decreased due to alteration of the intestinal mucosa	monitor for response to quinolone therapy, adjust quinolone dose as necessary

### SUPPLY AND STORAGE:

**Injection:** Fresenius Kabi Canada Ltd. supplies mitoxantrone as 20 mg ready-to-use, single-use (preservative free) vials in a concentration of 2 mg/mL. Store at room temperature.<sup>11</sup>

For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

### SOLUTION PREPARATION AND COMPATIBILITY:

For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

**Additional information:** should be diluted to at least 50 mL prior to use<sup>3,6,7</sup>

**Compatibility:** consult detailed reference

### PARENTERAL ADMINISTRATION:

BC Cancer administration guideline noted in **bold, italics**

Subcutaneous <sup>3</sup>	not recommended
Intramuscular <sup>3</sup>	not recommended
Direct intravenous	not recommended; has been used <sup>5,41-43</sup>
Intermittent infusion <sup>2,3</sup>	slowly ( <b>over 3-5 minutes</b> ; typically given over 15-30 minutes) <b>into tubing of running IV</b> ; see <a href="#">Systemic Therapy Policy III-20: Prevention and Management of Extravasation of Chemotherapy</a>

	BC Cancer administration guideline noted in <b><i>bold, italics</i></b>
Continuous infusion <sup>1,5</sup>	has been used
Intraperitoneal <sup>3,8</sup>	has been used
Intrapleural <sup>44</sup>	investigational
Intrathecal <sup>3</sup>	not recommended; neuropathy and neurotoxicity including paralysis, seizures, and bowel and bladder dysfunction have occurred
Intra-arterial <sup>3</sup>	not recommended; local/regional neuropathy which may be irreversible has been reported
Intravesical <sup>45,46</sup>	investigational

### DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response, and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

#### Adults:

	BC Cancer usual dose noted in <b><i>bold, italics</i></b>
<i>Intravenous:</i>	<p>Cycle Length: <b>3-4 weeks</b> <sup>2,3,5,10:</sup> <b>12-14 mg/m<sup>2</sup> IV for one dose on day 1</b> (total dose per cycle 12-14 mg/m<sup>2</sup>)</p> <p>induction <sup>3:</sup> 12 mg/m<sup>2</sup> IV once daily for 5 consecutive days starting on day 1 (total dose 60 mg/m<sup>2</sup>)</p> <p>induction and re-induction <sup>2,3:</sup> 10-12 mg/m<sup>2</sup> IV once daily for 2-3 consecutive days starting on day 1 (total dose per cycle 20-36 mg/m<sup>2</sup>)</p> <p>consolidation: <sup>2,3:</sup> 12 mg/m<sup>2</sup> IV once daily for 2 consecutive days starting on day 1 (total dose per cycle 24 mg/m<sup>2</sup>)</p>
<i>Suggested maximum cumulative dose</i> <sup>47-49:</sup>	160 mg/m <sup>2</sup>
<i>Concurrent radiation:</i>	has been used <sup>50-53</sup>
<i>Dosage in myelosuppression:</i>	modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix "Dosage Modification for Myelosuppression"
<i>Dosage in renal failure:</i>	safety and effectiveness have not been established <sup>3</sup> limited renal excretion, adjustment likely not required <sup>2</sup>
<i>Dosage in hepatic failure:</i>	consider dosage adjustment <sup>5;</sup> no dosing details found contraindicated in severe hepatic impairment <sup>3</sup>

*Dosage in dialysis:* extensive tissue binding; unlikely cleared by dialysis; supplemental dose not required <sup>5,54</sup>

**Children:**

safety and effectiveness have not been established <sup>3</sup>; has been used <sup>1,3,55</sup>

*Intravenous:*

Cycle Length:

n/a <sup>1,55</sup>: 8-12 mg/m<sup>2</sup> IV once daily for 3-5 consecutive days starting on day 1  
(total dose 24-60 mg/m<sup>2</sup>)

n/a <sup>1</sup>: 0.4 mg/kg/day IV once daily for 3-5 consecutive days starting on day 1  
(total dose 1.2-2.0 mg/kg)

n/a <sup>1</sup>: 12 mg/m<sup>2</sup> IV once daily for 2-3 consecutive days starting on day 1  
(total dose 24-36 mg/m<sup>2</sup>)

3-4 weeks <sup>1</sup>: 18-20 mg/m<sup>2</sup> IV for one dose on day 1  
(total dose per cycle 18-20 mg/m<sup>2</sup>)

**REFERENCES:**

- Rose BD editor. Mitoxantrone: Pediatric drug information. UpToDate 15.3 ed. : UpToDate®; 2008. [www.uptodate.com](http://www.uptodate.com)
- McEvoy GK, editor. AHFS 2007 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.; p. 1143–1145
- Hospira Healthcare Corporation. Mitoxantrone Injection, USP Product Monograph. Saint-Laurent, Quebec; 13 June, 2007.
- Floyd J, Morgan JP, Perry MC. Cardiotoxicity of anthracycline-like chemotherapy agents. UpToDate 15.3 ed. : UpToDate®; 2007. [www.uptodate.com](http://www.uptodate.com)
- Rose BD editor. Mitoxantrone. UpToDate 15.3 ed. : UpToDate®; 2008. [www.uptodate.com](http://www.uptodate.com)
- Pharmaceutical Partners of Canada. Mitoxantrone Injection Package Insert. Richmond Hill, Ontario; February, 2007.
- Novopharm Limited. Mitoxantrone Injection Product Monograph. Toronto, Ontario; 19 May, 2005.
- DRUGDEX® Evaluations (database on the Internet). Mitoxantrone. Thomson MICROMEDEX®; Accessed 25 January, 2008. Available at: [www.micromedex.com](http://www.micromedex.com)
- Ehninger G, Schuler U, Proksch B, et al. Pharmacokinetics and metabolism of mitoxantrone. Clin Pharmacokinet. ; 1990;18(5):365–380
- BC Cancer Agency Genitourinary Tumour Group. (GUPMX) BCCA Protocol Summary for Palliative Therapy for Hormone Refractory Prostate Cancer Using Mitoxantrone and Prednisone. Vancouver, British Columbia: BC Cancer Agency; 1 February , 2007.
- Fresenius Kabi Canada Ltd. Mitoxantrone injection® product monograph. Richmond Hill, Ontario; September 28, 2016.
- Lemez P, Urbanek V. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients. Neoplasma ; 2005;52(5):398–401
- Lyly Le MD. BC Cancer Agency Genitourinary Tumour Group. Personal communication. 12 March, 2008.
- BC Cancer Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy III-20: Prevention and Management of Extravasation of Chemotherapy. Vancouver, British Columbia: BC Cancer; March 1 , 2021.
- BC Cancer Supportive Care Tumour Group. (SCNAUSEA) BC Cancer Guidelines for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer; September 1 , 2022.
- Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf ; 2005;4(2):219–234
- Pfizer Canada Inc. IDAMYCIN® product monograph. Kirkland, Quebec; 19 February , 2009.
- Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol ; September 01, 2007;25(25):3991–4008



19. McEvoy GK, editor. AHFS 2005 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.; 2005.
20. Mayne Pharma (Canada) Inc. Doxorubicin Product Monograph. Montreal, Quebec; 2002.
21. Novopharm Limited. Doxorubicin Product Monograph. Scarborough, Ontario; 1996.
22. Repchinsky C, BSP. Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists association; 2005. p. 676
23. Rose BD editor. Cardiotoxicity in patients receiving chemotherapy. Waltham, Massachusetts: UpToDate®; accessed 22 September, 2005.
24. Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology. *J Clin Oncol* ; June 15, 2002;20(12):2895–2903
25. Hensley M, Hagerty K, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. *J Clin Oncol* ; 2009;27(1):127–145
26. Keefe DL. Anthracycline-induced cardiomyopathy. *Semin Oncol* ; Aug, 2001;28(4 Suppl 12):2–7
27. Le Deley M, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. *J Clin Oncol* ; March 15, 2003;21(6):1074–1081
28. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Children's Oncology Group; Accessed 4 March, 2011. Available at: [www.survivorshipguidelines.org](http://www.survivorshipguidelines.org)
29. Teva Canada Limited. Daunorubicin hydrochloride for injection product monograph. Toronto, Ontario; November 19, 2013.
30. Accord Healthcare Inc. Doxorubicin injection product monograph. Kirkland, Quebec; November 19, 2018.
31. Pfizer Canada Inc. Epirubicin hydrochloride injection product monograph. Kirkland, Quebec; 6 October, 2017.
32. Pfizer Canada Inc. IDARUBICIN® product monograph. Kirkland, Quebec; 19 August, 2014.
33. Anderlini P, Benjamin RS, Wong FC, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. *J Clin Oncol* ; 1995;13(11):2827–2834
34. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. *J Clin Oncol* ; 1996;14(6):1756–1764
35. DeVita VT, Hellman S, Rosenberg SA. *Cancer Principles & Practice of Oncology*. 6th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2001. p. 2640
36. Leukemia/Bone Marrow Transplant Program of British Columbia. *Leukemia/BMT Manual*. 4th ed. Vancouver, British Columbia: Vancouver Hospital and Health Sciences Centre / BC Cancer Agency; 2003. p. 27
37. Sanofi-Synthelabo. FASTURTEC® product information. Markham, Ontario; 2004.
38. Leukemia/Bone Marrow Transplant Program of British Columbia. *Leukemia/BMT Manual*. E-Edition ed. Vancouver, British Columbia: Vancouver Hospital and Health Sciences Centre / BC Cancer Agency; 2010. p. 93–94
39. Drug Interaction Facts (database on the Internet). Procarbazine. Facts and Comparisons 4.0; Accessed 7 March, 2008. Available at: <http://online.factsandcomparisons.com>
40. Josephine Holmes. Manager Regulatory Affairs, Pharmaceutical Partners of Canada Inc. Personal communication. 28 Jan, 2008.
41. Hainsworth JD, Jones SE, Mennel RG, et al. Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: A phase II trial. *Journal of Clinical Oncology* ; May, 1996;14(5):1611–1616
42. Carmo-Pereira J, Costa FO, Henriques E. Mitoxantrone, folinic acid, 5-fluorouracil and prednisone as first-line chemotherapy for advanced breast carcinoma. A phase II study. *European Journal of Cancer Part A: General Topics* ; 1993;29(13):1814–1816
43. Kakolyris S, Samonis G, Koukourakis M, et al. First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonal therapy with tamoxifen and megestrol acetate in advanced breast cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials* ; Jun, 1999;22(3):273–277
44. Windsor PG, Como JA, Windsor KS. Sclerotherapy for malignant pleural effusions: Alternatives to tetracycline. *South.Med.J.* ; 1994;87(7):709–714
45. Flamm J, Donner G, Oberleitner S, et al. (. Adjuvant intravesical mitoxantrone after transurethral resection of primary superficial transitional cell carcinoma of the bladder. A prospective randomised study. *European Journal of Cancer Part A: General Topics* ; 1995;31(2):143–146
46. Porter P, Cornaby AJ, Al-Hilali M, et al. Primary lymphoma of the bladder treated successfully with mitoxantrone gel. *Postgrad.Med.J.* ; Oct, 1999;75(888):609–610
47. Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. *Can J Cardiol* ; November, 2017;33(11):1342–1433
48. Zamorano JL, Lancellotti P, Rodriguez Muñoz D;V., et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. (The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)). *Eur Heart J* ; 2016;37(16):2768–2801
49. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. *Cancer Treat Rev* ; November 9, 2010:1–12
50. Toledano A, Azria D, Garaud P, et al. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: Final results of the ARCOSEIN trial. *Journal of Clinical Oncology* ; 01 Feb, 2007;25(4):405–410

51. Roesse J, De La Lande B, Bertheault-Cvitkovic F, et al. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: Final results. *International Journal of Radiation Oncology Biology Physics* ; 15 Mar, 2006;64(4):1072–1080
52. Macquart-Moulin G, Viens P, Genre D, et al. Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma: Side effects, quality of life, and daily organization. *Cancer* ; 15 May, 1999;85(10):2190–2199
53. Gedlicka C, Schull B, Formanek M, et al. Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies. *Anticancer Drugs* ; June, 2002;13(5):491–495
54. Aronoff GR, Bennett WM, Berns JS, Brier ME, et al. *Drug Prescribing in Renal Failure: Dosing guidelines for adults and children*. 5th ed. Philadelphia, Pennsylvania: American College of Physicians; 2007. p. 101
55. Pizzo P, Poplack D. *Principles and Practice of Pediatric Oncology*. 5th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2006. p. 303